13F Holdings
中文EN

JAZZ Jazz Pharmaceuticals plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%

Margins

Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%

Returns

ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B
R&D expense$782.74M$884.00M$849.66M$590.45M$505.75M
SG&A expense$1.81B$1.39B$1.34B$1.42B$1.45B
Operating income-$430.24M$716.63M$578.58M-$65.53M$170.28M
Interest expense——$32.80M$32.80M$89.90M
Pretax income-$627.86M$470.35M$297.93M-$372.78M-$112.84M
Income tax-$272.44M-$91.43M-$119.91M-$158.65M$216.12M
Net income-$356.15M$560.12M$414.83M-$224.06M-$329.67M
EBITDA-$388.64M$749.43M$608.98M-$35.23M$196.98M
EPS (basic)-5.849.066.55-3.58-5.52
EPS (diluted)-5.848.656.10-3.58-5.52
Weighted avg. shares (diluted)60.98M66.01M72.07M62.54M59.69M
Balance sheet
Cash & equivalents$1.39B$2.41B$1.51B$881.48M$591.45M
Receivables$830.70M$716.76M$705.79M$651.49M$563.36M
Inventory$417.00M$480.44M$597.04M$714.06M$1.07B
Current assets$4.17B$4.63B$3.44B$2.61B$2.61B
PP&E, net$199.90M$173.41M$169.65M$228.05M$256.84M
Goodwill$1.83B$1.72B$1.75B$1.69B$1.83B
Intangibles$4.43B$4.76B$5.42B$5.79B$7.15B
Total assets$11.66B$12.01B$11.39B$10.84B$12.30B
Current liabilities$2.24B$1.04B$1.54B$933.19M$809.30M
Short-term debt$1.03B$31.00M$604.95M$31.00M$31.00M
Long-term debt$4.33B$6.08B$5.11B$5.69B$6.02B
Total debt$5.36B$6.11B$5.71B$5.72B$6.05B
Total liabilities$7.34B$7.92B$7.66B$7.75B$8.33B
Shareholders' equity$4.32B$4.09B$3.74B$3.09B$3.97B
Net debt$3.97B$3.70B$4.21B$4.84B$5.46B
Shares outstanding61.44M60.63M62.26M63.21M61.63M
Cash flow statement
Operating cash flow$1.36B$1.40B$1.09B$1.27B$778.51M
Capital expenditure$58.75M$38.07M$23.96M$29.05M$27.64M
Free cash flow$1.30B$1.36B$1.07B$1.24B$750.87M
Investing cash flow-$1.51B-$508.19M-$163.06M-$446.23M-$5.21B
Financing cash flow-$873.38M$20.52M-$305.25M-$529.49M$3.97B
Depreciation & amortization$41.60M$32.80M$30.40M$30.30M$26.70M
Stock-based compensation$291.13M$248.04M$226.84M$222.00M$189.01M
Share buybacks$125.02M$311.43M$269.76M$54,000$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.